The DGCR5-S variant inhibits the anti-inflammatory activity of tristetraprolin by safeguarding it from dephosphorylation by protein phosphatase 2 (PP2A), consequently fostering tumor-associated inflammation. Here, DGCR5 is linked to neoplasm.